UMIN-CTR Clinical Trial

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000009545
Receipt No. R000010960
Official scientific title of the study A cross sectional study of Quality of Life in long-term adult survivors after allogeneic hematopoietic stem cell transplantation
Date of disclosure of the study information 2012/12/15
Last modified on 2017/01/11 (Ver. 7)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study A cross sectional study of Quality of Life in long-term adult survivors after allogeneic hematopoietic stem cell transplantation
Title of the study (Brief title) QOL in adult survivors after hematopoietic stem cell transplantation
Region
Japan

Condition
Condition Hematopoietic stem cell trans-
plantation targeted diseases such as hematological diseases
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To improve Quality of Life (QOL) in patients after transplantation by a cross sectional study of QOL in long-term adult survivors after allogeneic hematopoietic stem cell transplantation.
Basic objectives2 Others
Basic objectives -Others QOL
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes We will examine QOL of adult survivors which assessed by SF-36, FACT-BMT and VAS described below.
(1)SF-36: Compare QOL of patients with that of same sex, coeval national certified value.
(2)FACT-BMT: Examine factors associated with QOL.
(3)VAS: Compare VAS of patients and their attending physician and examine associated factors.
(4)Factors which are associated with QOL
*Donor and type of transplantation
*Conditioning regimens and total body irradiation
*Years after transplantation, reintegration into society, connubiality and restoration of gonadal function
(5)Compare background factors of patients who are engaged in this study with who disapproved or unable to explain this study.
(6)Compare patients who are included in this study and patients who are included in the pediatric study.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1)Patients who aged 16 or above at transplantation and 20 or above at study.
(2)Patients who were transplanted at adult department.
(3)Patients who survived for two years and above after last transplantation without relapse.
(4)Patients who signed a written informed consents.
(5)Patients who can read Japanese questionnaire.
Key exclusion criteria (1)Patients who disapproved of TRUMP search.
(2)Patients who are disqualified by his attending physician.
Target sample size 300

Research contact person
Name of lead principal investigator Shuichi Taniguchi M.D.
Organization Late Effects / Quality of Life Working Group, the Japan Society for Hematopietic Cell Tranplantation
(Toranomon Hospital)
Division name Department of Hematology
Address 2-2 Toranomon2-chome, Minato-ku, Tokyo, 105-8470 Japan
TEL 03-3588-1111
Email taniguchi-s@toranomon.gr.jp

Public contact
Name of contact person Kumi Oshima, M.D.
Organization Hiroshima University Research Institute for Radiation Biology and Medicine
Division name Department of Hematology and Oncology, Research Center for Radiation Casualty Medicine
Address 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8553, Japan
TEL 082-257-5861
Homepage URL http://jshct.com
Email kumioshima-tky@umin.ac.jp

Sponsor
Institute Late Effects / Quality of Life Working Group, the Japan Society for Hematopietic Cell Tranplantation
Institute
Department

Funding Source
Organization Research Grant for Allergic Disease and Immunology (H23-013) from the Japanese Ministry of Health, Labor, and Welfare.
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor Department of HSCT Data Management and Biostatistics
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2012 Year 12 Month 15 Day

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2012 Year 12 Month 06 Day
Anticipated trial start date
2012 Year 12 Month 07 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information This is a cross-sectional observational study. Long-term survivors without relapse after hematopoietic stem cell transplantation, who fulfill inclusion criteria, who visited participating centers during the registration period (one year) are the subjects for this study.

Management information
Registered date
2012 Year 12 Month 14 Day
Last modified on
2017 Year 01 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010960